Yes, Loxo is still plan­ning on seek­ing an ac­cel­er­at­ed OK, in case you had for­got­ten

Back in the spring, Loxo On­col­o­gy $LOXO was ready to pounce with an ear­ly snap­shot of some clin­i­cal re­spons­es to its lead can­cer drug, a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA